Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.55 |
| ▸ | PDE4A | P27815 | 7/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29125419 | 0.95 | PDE4D (0.55) | PDE4DPDE4BPDE4APDE4CHTT | |
| SCHEMBL29125417 | 0.95 | PDE4D (0.55) | PDE4DPDE4BPDE4APDE4CHTT | |
| SCHEMBL27289091 | 0.86 | ALDH1A1 (0.45) | PDE4DPDE4BPDE4APDE4CNPSR1 | |
| SCHEMBL1157300 | 0.85 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CHTT | |
| SCHEMBL31481195 | 0.83 | HSPB1 (0.45) | PDE4DPDE4BPDE4APDE4CKMT2A | |
| SCHEMBL21295348 | 0.83 | CYP19A1 (0.42) | PDE4DPDE4BPDE4APDE4CHTT | |
| SCHEMBL16385491 | 0.83 | TDP1 (0.51) | PDE4DPDE4BPDE4APDE4CHTT | |
| SCHEMBL30684940 | 0.83 | SCD (0.51) | PDE4DPDE4BPDE4APDE4CHTT | |
| SCHEMBL21295551 | 0.83 | NTRK1 (0.56) | PDE4DPDE4BPDE4APDE4CTDP1 | |
| SCHEMBL30744010 | 0.83 | NTRK1 (0.56) | PDE4DPDE4BPDE4APDE4CTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2011-02-24 | — | — | US | disclosed |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7205320-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2007-04-05 | — | — | US | disclosed |
| EP-0994100-B1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | NIKKEN CHEMICALS CO LTD (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699890-B2 | N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES | MEMORY PHARMACEUTICALS CORP. | 2004-03-02 | — | — | US | disclosed |
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-08-07 | — | — | US | disclosed |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2002-10-17 | — | — | US | disclosed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | PDE4D 8/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | PDE4D 8/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.